A review on insulin-producing beta cell: regenerative role of drugs acting on DYRK1A, GLP-1 and DPP-4 receptors

Abstract

Approximately 422 million people have diabetes all over the world. The regeneration of the beta cell has been investigated for a longer time by scientists with the hope of newer potential opportunities, thus contributing to the treatment of diabetes. Beta-cell regeneration is a mechanism of producing new beta cells in the pancreas, which is responsible for the secretion of insulin, currently on pre-clinical trials. In this study, the action of each three receptors – GLP-1, DPP-4, and DYRK1A has been discussed. Their possibility of combination in the regeneration of damaged beta cells for the welfare of diabetic patients by comparing the ability of each of the receptors to regenerate beta cells as well as the combination of actions on these receptors produce any better effect or not has also been analyzed. However, millions of people with diabetes have a ray of hope as the current use of GLP-1 and DYRK1A indicates a prospective technique based on DYRK1A inhibition with the GLP-1 receptor. Moreover, it is also a fact that still there is no evidence of any potential combined treatment with the use of GLP-1 and DPP-4 for diabetic patients.